{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:21:45Z","timestamp":1793877705459,"version":"4.7.0"},"reference-count":20,"publisher":"The Journal of Rheumatology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective.<\/jats:title>\n                    <jats:p>To evaluate clinical and patient-reported outcomes (PROs) at 6 months after secukinumab initiation in US patients with psoriatic arthritis (PsA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>Patients with PsA in the CorEvitas Psoriatic Arthritis\/Spondyloarthritis Registry who initiated secukinumab between April 1, 2017, and December 2, 2019, and maintained secukinumab at their 6-month follow-up visit were included. Achievement of minimal disease activity (MDA) among patients not in MDA at initiation; resolution (ie, no evidence) of tender and swollen joint counts, enthesitis, and dactylitis among patients with \u2265 1 of these at initiation; and change in disease activity and PROs were evaluated at 6 months in all patients and in patients who received secukinumab as a first-line biologic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Of the 100 eligible patients included, most (83.0%) were biologic experienced and 17.0% initiated secukinumab as a first-line biologic. At initiation, 75\/90 patients (83.3%) with available data were not in MDA; 26\/71 (36.6%) with follow-up data achieved MDA at 6 months. Further, 28\/68 patients (41.2%) with \u2265 1 tender joint, 24\/54 (44.4%) with \u2265 1 swollen joint, 17\/28 (60.7%) with enthesitis, and 9\/12 (75.0%) with dactylitis at initiation achieved resolution at 6 months. Improvements in clinical manifestations, PRO measures, and work productivity and activity were observed after 6 months among patients with PsA who initiated and maintained secukinumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>In this real-world population, patients with PsA who received and maintained secukinumab for 6 months achieved MDA in proportions consistent with clinical trials and demonstrated improvements in clinical manifestations and PROs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.211033","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T08:25:35Z","timestamp":1650011135000},"page":"700-706","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis\/Spondyloarthritis Registry"],"prefix":"10.3899","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J.","family":"Mease","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Blachley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0056-997X","authenticated-orcid":false,"given":"Blessing","family":"Dube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"McLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-0775","authenticated-orcid":false,"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"key":"2022070105203839000_49.7.700.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.07.003"},{"key":"2022070105203839000_49.7.700.2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000638"},{"key":"2022070105203839000_49.7.700.3","unstructured":"Cosentyx (secukinumab) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2021."},{"key":"2022070105203839000_49.7.700.4","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3389\/fmed.2020.00288","article-title":"Real life efficacy and safety of secukinumab in biologic-experienced patients with psoriatic arthritis","volume":"7","author":"Klavdianou","year":"2020","journal-title":"Front Med"},{"key":"2022070105203839000_49.7.700.5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40744-018-0137-z","article-title":"Characteristics of patients with psoriatic arthritis receiving secukinumab and reasons for initiation: a US retrospective medical chart review","volume":"6","author":"Sunkureddi","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2022070105203839000_49.7.700.6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200371"},{"key":"2022070105203839000_49.7.700.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"2022070105203839000_49.7.700.8","unstructured":"StataCorp. Stata statistical software: release 15 . College Station, TX: StataCorp LLC; 2017."},{"key":"2022070105203839000_49.7.700.9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150805"},{"key":"2022070105203839000_49.7.700.10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13075-017-1277-1","article-title":"MAAPS study group. Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study","volume":"19","author":"Queiro","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2022070105203839000_49.7.700.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212687"},{"key":"2022070105203839000_49.7.700.12","first-page":"10","article-title":"Secukinumab provides sustained improvements in subgroup analyses of joint tenderness and swelling in patients with psoriatic arthritis: 5-year results from the phase 3 FUTURE 2 study [abstract]","volume":"72","author":"McInnes","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2022070105203839000_49.7.700.13","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/acr.23537","article-title":"Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2-year results from a multicenter, randomized, double-blind, parallel-group, placebo-controlled phase III study","volume":"70","author":"Coates","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2022070105203839000_49.7.700.14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","article-title":"FUTURE 3 study group. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2022070105203839000_49.7.700.15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/annrheumdis-2015-209055","article-title":"FUTURE 1 study group. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)","volume":"76","author":"Strand","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022070105203839000_49.7.700.16","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/14712598.2020.1761957","article-title":"One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study","volume":"20","author":"Chimenti","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"2022070105203839000_49.7.700.17","unstructured":"Michelsen B , Georgiadis S , Di Giuseppe D , Real-world 6 and 12-month drug retention, remission and response rates of secukinumab in 2,017 psoriatic arthritis patients in 13 European countries. Arthritis Care Res 2021 Jan 18 (Epub ahead of print)."},{"key":"2022070105203839000_49.7.700.18","doi-asserted-by":"crossref","first-page":"1759720X19858510","DOI":"10.1177\/1759720X19858510","article-title":"Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis","volume":"11","author":"Elliott","year":"2019","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2022070105203839000_49.7.700.19","doi-asserted-by":"crossref","first-page":"e001519","DOI":"10.1136\/rmdopen-2020-001519","article-title":"Spondyloarthritis and Psoriatic Arthritis SIR Study Group \u201cAntonio Spadaro\u201d. Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study","volume":"7","author":"Ramonda","year":"2021","journal-title":"RMD Open"},{"key":"2022070105203839000_49.7.700.20","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1093\/rheumatology\/keaa591","article-title":"A comparison of physical function instruments in psoriatic arthritis: HAQ-DI vs MDHAQ vs PROMIS10 global physical health","volume":"60","author":"Wan","year":"2021","journal-title":"Rheumatology"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.211033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T08:22:21Z","timestamp":1656663741000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.211033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,1]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.3899\/jrheum.211033"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.211033","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,15]]}}}